Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy in non-renal carcinomas.

U Keilholz1

  • 1Department of Medicine III, Charité, Campus Benjamin Franklin, Berlin, Germany. ulrich.keilholz@medizin-fu-berlin.de

Der Urologe. Ausg. A
|May 19, 2004
PubMed
Summary

Modern immunotherapy for cancer relies on recombinant protein technology and understanding how cells present peptides to T lymphocytes. These advances enable cytokine treatments and tumor vaccines for various human neoplasms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO open·2026
Same author

17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?

ESMO gastrointestinal oncology·2026
Same author

Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers.

ESMO open·2025
Same author

Estimating the prevalence of mental disorders in patients with newly diagnosed cancer in relation to socioeconomic status: a multicenter prospective observational study.

ESMO open·2024
Same author

The German Network for Personalized Medicine to enhance patient care and translational research.

Nature medicine·2023
Same author

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Modern cancer immunotherapy has been significantly advanced by two key discoveries.
  • The first is the development of recombinant protein production technology, enabling clinical use of cytokines and antibodies.
  • The second is the understanding of peptide presentation on HLA molecules to T lymphocytes, forming the basis for tumor vaccines.

Purpose of the Study:

  • To review the principles and outcomes of cytokine therapy and vaccines in human neoplasms.
  • To focus on applications beyond renal cancer.

Main Methods:

  • Review of scientific literature on immunotherapy, recombinant protein technology, and tumor vaccines.
  • Summary of clinical applications and results of cytokine treatments and vaccines.

Main Results:

  • Recombinant protein technology has led to the clinical use of cytokines, chimeric, and humanized antibodies.
  • Peptide presentation by HLA molecules is fundamental to developing modern tumor vaccines.
  • Cytokine treatments and vaccines show promise in various human neoplasms.

Conclusions:

  • Recombinant protein technology and peptide-MHC complex recognition are cornerstones of modern cancer immunotherapy.
  • These discoveries have paved the way for novel therapeutic strategies including cytokine therapy and tumor vaccines.
  • Further research and application in human neoplasms beyond renal cancer are warranted.

Related Experiment Videos